))
Few IPOs but plenty of follow-on for biotech in 2023
Manage episode 396923115 series 2838531
内容由RBC Capital Markets提供。所有播客内容（包括剧集、图形和播客描述）均由 RBC Capital Markets 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
After a year of stark contrasts in the public and private equity markets for healthcare, 2024 is shaping up to be another mixed outlook. While biotech continues to bolster the market, albeit more in follow-on offerings than IPOs, and HCIT and healthcare services have tailwinds, the medtech and value-based care subsectors have challenges as well as opportunities. Join our Co-Heads of Healthcare Equity Markets for their insights into the year ahead.
45集单集
分享
